Kristina V. Shcherbatyuk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kristina V. Shcherbatyuk has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Anstasiya V. Ovchinnikova
N.I. Pirogov Russian National Research Medical University
2 shared publications - Dina S. Gutorova
N.I. Pirogov Russian National Research Medical University
2 shared publications - Georgiy N. Golukhov
Pirogov Russian National Research Medical University, Moscow, Russia
2 shared publications - Laura M. Kappusheva
N.I. Pirogov Russian National Research Medical University
2 shared publications - Lyudmila Mikhaylovna Mikhaleva
Avtsyn Research Institute of Human Morphology of Federal State Budgetary Scientific Institution “Petrovsky National Research Centre of Surgery”, 117418 Moscow, Russia
2 shared publications - Valentina G. Breusenko
N.I. Pirogov Russian National Research Medical University
2 shared publications
Latest Publications
- Open Access
- 26 February 2026
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 174 (2) , 630-642
Diagnostic accuracy of phosphatase and tensin homolog loss in differentiating between atypical endometrial hyperplasia/endometrioid intraepithelial neoplasia and non‐atypical endometrial hyperplasia: A systematic review and meta‐analysis
Background: Accurate distinction between atypical endometrial hyperplasia/endometrioid intraepithelial neoplasia (AH/EIN) and non‐atypical endometrial hyperplasia (EH) determines whether patients require hysterectomy or can be managed conservatively. Phosphatase and tensin homolog (PTEN) loss has been proposed as an immunohistochemical (IHC) marker to support diagnostic evaluation. Objectives: This study evaluates the diagnostic value of PTEN IHC for the diagnosis of AH/EIN and to explore how PTEN assessment methods affect diagnostic performance. Method: PubMed, Cochrane Library, ClinicalTrials.gov , Scopus, Embase, MEDLINE, and Web of Science were searched from database inception up to June 1, 2025. Studies reporting PTEN IHC in women with histologically confirmed AH/EIN or non‐atypical EH. Two reviewers independently screened records, extracted data, and assessed risk of bias with QUADAS‐2. Pooled diagnostic estimates and summary receiver‐operating characteristics (SROC) curves were calculated using a bivariate random‐effects model with subgroup analysis and the IHC method. Results: Twenty‐seven studies (2274 women) were included. Pooled sensitivity was 58.0% (95% confidence interval [CI], 40.8–73.4) and specificity 84.7% (95% CI, 67–93.8). The diagnostic odds ratio was 3.695 (95% CI, 2.501–5.460), with an area under the SROC of 0.679. The PTEN assessment method based on percentage of stained cells and staining intensity showed the highest the area under the curve of 0.744 among the methods evaluated in the subgroup analysis. Conclusions: PTEN IHC assessment demonstrated good specificity and might serve as a complementary tool in diagnosing AH/EIN, helping to reduce the number of incorrect diagnoses of atypia and unnecessary hysterectomies in clinical practice. Its limited sensitivity precludes its use as a standalone marker. Standardized staining protocols and multi‐marker strategies are needed. PROSPERO Registration: CRD42024607623, registration date the 29 October 2024.
- 26 February 2026
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 174 (2) , 630-642
Open AccessDiagnostic accuracy of phosphatase and tensin homolog loss in differentiating between atypical endometrial hyperplasia/endometrioid intraepithelial neoplasia and non‐atypical endometrial hyperplasia: A systematic review and meta‐analysis
Background: Accurate distinction between atypical endometrial hyperplasia/endometrioid intraepithelial neoplasia (AH/EIN) and non‐atypical endometrial hyperplasia (EH) determines whether patients require hysterectomy or can be managed conservatively. Phosphatase and tensin homolog (PTEN) loss has been proposed as an immunohistochemical (IHC) marker to support diagnostic evaluation. Objectives: This study evaluates the diagnostic value of PTEN IHC for the diagnosis of AH/EIN and to explore how PTEN assessment methods affect diagnostic performance. Method: PubMed, Cochrane Library, ClinicalTrials.gov , Scopus, Embase, MEDLINE, and Web of Science were searched from database inception up to June 1, 2025. Studies reporting PTEN IHC in women with histologically confirmed AH/EIN or non‐atypical EH. Two reviewers independently screened records, extracted data, and assessed risk of bias with QUADAS‐2. Pooled diagnostic estimates and summary receiver‐operating characteristics (SROC) curves were calculated using a bivariate random‐effects model with subgroup analysis and the IHC method. Results: Twenty‐seven studies (2274 women) were included. Pooled sensitivity was 58.0% (95% confidence interval [CI], 40.8–73.4) and specificity 84.7% (95% CI, 67–93.8). The diagnostic odds ratio was 3.695 (95% CI, 2.501–5.460), with an area under the SROC of 0.679. The PTEN assessment method based on percentage of stained cells and staining intensity showed the highest the area under the curve of 0.744 among the methods evaluated in the subgroup analysis. Conclusions: PTEN IHC assessment demonstrated good specificity and might serve as a complementary tool in diagnosing AH/EIN, helping to reduce the number of incorrect diagnoses of atypia and unnecessary hysterectomies in clinical practice. Its limited sensitivity precludes its use as a standalone marker. Standardized staining protocols and multi‐marker strategies are needed. PROSPERO Registration: CRD42024607623, registration date the 29 October 2024.
- Open Access
- 1 September 2023
- Published by ECO-Vector LLC in Morphology
- Vol. 160 (3) , 139-150
Prognostic significance of the immunohistochemical status of the endometrium as markers of therapy for endometrial hyperplasia
BACKGROUND: In patients of reproductive age with endometrial hyperplasia without atypia, hormonal treatment, and prognosis of response remain relevant issues. AIM: To increase the effectiveness of hormonal therapy for endometrial hyperplasia in patients of reproductive age with abnormal uterine bleeding, considering the receptivity, and proliferative activity of the endometrium. MATERIALS AND METHODS: A total of 179 patients of reproductive age with abnormal uterine bleeding and endometrial hyperplasia were examined. After the removal of the endometrial tissue, hormonal therapy was performed for 6 months: 101 patients received dydrogesterone 20 mg/day, and 78 patients received norethisterone acetate 10 mg/day. The expression levels of estrogen receptor- (Er), progesterone receptor (PR), and Ki67 in the endometrial tissue were determined by immunohistochemistry at baseline and 3 months after the treatment. The comparison group consisted of 18 women without gynecological pathology. Variation statistics methods were used to process the data, the differences between the indicators groups of patients were considered significant at p 0.05. RESULTS: Before treatment, the expression levels of ER, PR in both compartments, and Ki-67 in the glands were lower (p 0.05) in the endometrial hyperplasia group than in the control group. Remission was achieved in 77 (76.24%) (dydrogesterone) and 62 (79.49%) (norethisterone acetate) patients. Initially, the expression level of ER in the glands and stroma of endometrial hyperplasia was lower (p 0.05) than that in the comparison group; the resistant group had a lower (p 0.05) response to treatment. The expression of PR in the resistant group was lower (p 0.05) than that in the comparison group and remission group. The expression level of Ki67 in the response group was lower than that in the comparison group (p 0.05), and the expression in the stroma was lower than that in the resistant group (p 0.05). After treatment in both compartments, the expression levels of ER and PR were lower in the resistant group than in the comparison group and response group (p 0.05). A logistic regression equation was obtained with a set of predictors: ER (glands) + PR (glands and stroma) + Ki-67 (stroma) with a potential response to therapy of 93%. CONCLUSIONS: The specified predictive model is promising. The therapy was effective in 93% of cases.
- 1 September 2023
- Published by ECO-Vector LLC in Morphology
- Vol. 160 (3) , 139-150
Open AccessPrognostic significance of the immunohistochemical status of the endometrium as markers of therapy for endometrial hyperplasia
BACKGROUND: In patients of reproductive age with endometrial hyperplasia without atypia, hormonal treatment, and prognosis of response remain relevant issues. AIM: To increase the effectiveness of hormonal therapy for endometrial hyperplasia in patients of reproductive age with abnormal uterine bleeding, considering the receptivity, and proliferative activity of the endometrium. MATERIALS AND METHODS: A total of 179 patients of reproductive age with abnormal uterine bleeding and endometrial hyperplasia were examined. After the removal of the endometrial tissue, hormonal therapy was performed for 6 months: 101 patients received dydrogesterone 20 mg/day, and 78 patients received norethisterone acetate 10 mg/day. The expression levels of estrogen receptor- (Er), progesterone receptor (PR), and Ki67 in the endometrial tissue were determined by immunohistochemistry at baseline and 3 months after the treatment. The comparison group consisted of 18 women without gynecological pathology. Variation statistics methods were used to process the data, the differences between the indicators groups of patients were considered significant at p 0.05. RESULTS: Before treatment, the expression levels of ER, PR in both compartments, and Ki-67 in the glands were lower (p 0.05) in the endometrial hyperplasia group than in the control group. Remission was achieved in 77 (76.24%) (dydrogesterone) and 62 (79.49%) (norethisterone acetate) patients. Initially, the expression level of ER in the glands and stroma of endometrial hyperplasia was lower (p 0.05) than that in the comparison group; the resistant group had a lower (p 0.05) response to treatment. The expression of PR in the resistant group was lower (p 0.05) than that in the comparison group and remission group. The expression level of Ki67 in the response group was lower than that in the comparison group (p 0.05), and the expression in the stroma was lower than that in the resistant group (p 0.05). After treatment in both compartments, the expression levels of ER and PR were lower in the resistant group than in the comparison group and response group (p 0.05). A logistic regression equation was obtained with a set of predictors: ER (glands) + PR (glands and stroma) + Ki-67 (stroma) with a potential response to therapy of 93%. CONCLUSIONS: The specified predictive model is promising. The therapy was effective in 93% of cases.
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Bulletin of Obstetrician-Gynecologist
- Vol. 22 (5)
Hormonal therapy in patients of reproductive age with endometrial hyperplasia without atypia. Immunohistochemical predictors of efficacy
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценка иммуногистохимических параметров эндометрия у пациенток с гиперплазией эндометрия без атипии и аномальным маточным кровотечением (АМК) как предикторов эффективности гормональной терапии. МАТЕРИАЛ И МЕТОДЫ Обследованы 78 пациенток репродуктивного периода с АМК. Выполнены гистероскопия, раздельное диагностическое выскабливание слизистой оболочки матки. При гистологическом исследовании эндометрия выявлена гиперплазия эндометрия без атипии. Проведена терапия норэтистерона ацетатом в дозе 10 мг/сут в циклическом режиме в течение 6 мес. Через 3 мес после окончания лечения выполнена аспирационная биопсия эндометрия. По результатам гистологического исследования ретроспективно больные разделены на две группы: с эффектом от лечения (1-я группа) — 62 (79,49%) пациентки и без него (2-я группа) — 16 (20,51%), у которых была вновь диагностирована гиперплазия эндометрия. До лечения и после него проведено иммуногистохимическое исследование (ИГХИ) биоптатов эндометрия с определением экспрессии ERα, PR-A, PR-B, Ki-67. Контрольную группу составили 18 здоровых женщин. РЕЗУЛЬТАТЫ У пациенток с эффектом от терапии, по данным ИГХИ, выявлена исходно достоверно низкая экспрессия ERα в стромальном и железистом структурных компонентах эндометрия по сравнению с таковой у здоровых женщин. После лечения все показатели достигали нормы. У пациенток с вновь диагностированной гиперплазией эндометрия выявлены исходно низкие уровни экспрессии ERα, PR-A, PR-B в железистом и стромальном структурных компонентах эндометрия по сравнению с таковыми у здоровых женщин и пациенток 1-й группы (за исключением ERα в строме), после лечения эти изменения сохранялись. Экспрессия Ki-67 была исходно выше у пациенток 2-й группы по сравнению с этим показателем в 1-й группе. ЗАКЛЮЧЕНИЕ В ткани эндометрия до лечения целесообразно определять иммуногистохимические маркеры, которые могут быть перспективными предикторами эффективности гормональной терапии у пациенток репродуктивного возраста с гиперплазией эндометрия без атипии и аномальными маточными кровотечениями.
- 1 January 2022
- Published by Media Sphere Publishing Group in Russian Bulletin of Obstetrician-Gynecologist
- Vol. 22 (5)
Hormonal therapy in patients of reproductive age with endometrial hyperplasia without atypia. Immunohistochemical predictors of efficacy
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценка иммуногистохимических параметров эндометрия у пациенток с гиперплазией эндометрия без атипии и аномальным маточным кровотечением (АМК) как предикторов эффективности гормональной терапии. МАТЕРИАЛ И МЕТОДЫ Обследованы 78 пациенток репродуктивного периода с АМК. Выполнены гистероскопия, раздельное диагностическое выскабливание слизистой оболочки матки. При гистологическом исследовании эндометрия выявлена гиперплазия эндометрия без атипии. Проведена терапия норэтистерона ацетатом в дозе 10 мг/сут в циклическом режиме в течение 6 мес. Через 3 мес после окончания лечения выполнена аспирационная биопсия эндометрия. По результатам гистологического исследования ретроспективно больные разделены на две группы: с эффектом от лечения (1-я группа) — 62 (79,49%) пациентки и без него (2-я группа) — 16 (20,51%), у которых была вновь диагностирована гиперплазия эндометрия. До лечения и после него проведено иммуногистохимическое исследование (ИГХИ) биоптатов эндометрия с определением экспрессии ERα, PR-A, PR-B, Ki-67. Контрольную группу составили 18 здоровых женщин. РЕЗУЛЬТАТЫ У пациенток с эффектом от терапии, по данным ИГХИ, выявлена исходно достоверно низкая экспрессия ERα в стромальном и железистом структурных компонентах эндометрия по сравнению с таковой у здоровых женщин. После лечения все показатели достигали нормы. У пациенток с вновь диагностированной гиперплазией эндометрия выявлены исходно низкие уровни экспрессии ERα, PR-A, PR-B в железистом и стромальном структурных компонентах эндометрия по сравнению с таковыми у здоровых женщин и пациенток 1-й группы (за исключением ERα в строме), после лечения эти изменения сохранялись. Экспрессия Ki-67 была исходно выше у пациенток 2-й группы по сравнению с этим показателем в 1-й группе. ЗАКЛЮЧЕНИЕ В ткани эндометрия до лечения целесообразно определять иммуногистохимические маркеры, которые могут быть перспективными предикторами эффективности гормональной терапии у пациенток репродуктивного возраста с гиперплазией эндометрия без атипии и аномальными маточными кровотечениями.